Plain-English translation of NCT04701645 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers are testing a new implantable microdevice — a tiny implant about the size of a grain of rice — that may help doctors understand how an individual patient's cancer responds to different drugs. The device stays in a tumor sample for about 24 hours before your planned cancer surgery, then is removed when the tumor is surgically resected. This is a pilot study, meaning it's the first time doctors are examining whether this device can help personalize cancer treatment.
Right now, doctors choose chemotherapy drugs based on general guidelines, but every patient's cancer is different. This study exists to see if the microdevice can give doctors real-time information about which drugs work best against your specific cancer, potentially leading to more personalized and effective treatment.
You likely qualify if…
You likely don't qualify if…
If you join this study, a doctor will place several tiny microdevices into your tumor using a needle procedure (similar to a biopsy) about 24 hours before your already-planned cancer surgery. These devices will contain different chemotherapy drugs that will sit in your tumor tissue to test how your cancer responds to each one. After about one day, your surgeon will remove the devices when they perform your scheduled surgery to remove the tumor. You'll have lab work done before the procedure and follow-up care after surgery as part of standard treatment.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States